These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

115 related items for PubMed ID: 11023713

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Sensorineural hearing loss in children with thalassemia major in Northern Greece.
    Kontzoglou G, Koussi A, Tsatra J, Noussios G, Vital V, Sagarakis G, Athanassiou M.
    Int J Pediatr Otorhinolaryngol; 1996 May; 35(3):223-30. PubMed ID: 8762595
    [Abstract] [Full Text] [Related]

  • 4. Sensory neural hearing loss in beta-thalassemia major patients treated with deferoxamine.
    Shamsian BS, Aminasnafi A, Moghadassian H, Gachkar L, Arzanian MT, Alavi S, Esfehani H, Garallahi F, Amini R.
    Pediatr Hematol Oncol; 2008 Sep; 25(6):502-8. PubMed ID: 18728969
    [Abstract] [Full Text] [Related]

  • 5. Evaluation of the incidence of sensorineural hearing loss in beta-thalassemia major patients under regular chelation therapy with desferrioxamine.
    Karimi M, Asadi-Pooya AA, Khademi B, Asadi-Pooya K, Yarmohammadi H.
    Acta Haematol; 2002 Sep; 108(2):79-83. PubMed ID: 12187025
    [Abstract] [Full Text] [Related]

  • 6. Incidence of ototoxicity in pediatric patients with transfusion-dependent thalassemia who are less well-chelated by mono- and combined therapy of iron chelating agents.
    Tanphaichitr A, Kusuwan T, Limviriyakul S, Atipas S, Pooliam J, Sangpraypan T, Tanphaichitr VS, Viprakasit V.
    Hemoglobin; 2014 Sep; 38(5):345-50. PubMed ID: 25051423
    [Abstract] [Full Text] [Related]

  • 7. [Evaluation of desferrioxamine ototoxicity in thalassemic patients. Follow-up over a 5-year period and results].
    Sacco M, Meleleo D, Tricarico N, Greco Miani A, Serra E, Parlatore L.
    Minerva Pediatr; 1994 May; 46(5):225-30. PubMed ID: 8090141
    [Abstract] [Full Text] [Related]

  • 8. Audiologic and vestibular assessment in patients with β-thalassemia major receiving long-term transfusion therapy.
    Chao YH, Wu KH, Lin CY, Tsai MH, Peng CT, Wu HP, Lin CD.
    Pediatr Blood Cancer; 2013 Dec; 60(12):1963-6. PubMed ID: 23956204
    [Abstract] [Full Text] [Related]

  • 9. Desferrioxamine ototoxicity in an adult transfusion-dependent population.
    Chiodo AA, Alberti PW, Sher GD, Francombe WH, Tyler B.
    J Otolaryngol; 1997 Apr; 26(2):116-22. PubMed ID: 9106087
    [Abstract] [Full Text] [Related]

  • 10. Sensorineural hearing loss in β-thalassemia patients treated with iron chelation.
    Osma U, Kurtoglu E, Eyigor H, Yilmaz MD, Aygener N.
    Ear Nose Throat J; 2015 Dec; 94(12):481-5. PubMed ID: 26670754
    [Abstract] [Full Text] [Related]

  • 11. [Audiologic evaluation of patients with thalassemic syndromes treated with desferrioxamine B].
    Gaini RM, Moretti E, Boffa C, Terzoli S, Carnelli V.
    Pediatr Med Chir; 1988 Dec; 10(5):503-4. PubMed ID: 3241755
    [Abstract] [Full Text] [Related]

  • 12. Hearing loss and desferrioxamine in homozygous beta-thalassemia.
    Albera R, Pia F, Morra B, Lacilla M, Bianco L, Gabutti V, Piga A.
    Audiology; 1988 Dec; 27(4):207-14. PubMed ID: 3190562
    [Abstract] [Full Text] [Related]

  • 13. Auditory and visual toxicity during deferoxamine therapy in transfusion-dependent patients.
    Chen SH, Liang DC, Lin HC, Cheng SY, Chen LJ, Liu HC.
    J Pediatr Hematol Oncol; 2005 Dec; 27(12):651-3. PubMed ID: 16344669
    [Abstract] [Full Text] [Related]

  • 14. [Evaluation of auditory function in homozygous beta-thalassemia].
    Stura M, Arigliani R, Molinari AC, Tarantino V.
    Pediatr Med Chir; 1986 Dec; 8(5):703-5. PubMed ID: 3601700
    [Abstract] [Full Text] [Related]

  • 15. Combined therapy of silymarin and desferrioxamine in patients with beta-thalassemia major: a randomized double-blind clinical trial.
    Gharagozloo M, Moayedi B, Zakerinia M, Hamidi M, Karimi M, Maracy M, Amirghofran Z.
    Fundam Clin Pharmacol; 2009 Jun; 23(3):359-65. PubMed ID: 19453758
    [Abstract] [Full Text] [Related]

  • 16. Desferrioxamine ototoxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosage.
    Porter JB, Jaswon MS, Huehns ER, East CA, Hazell JW.
    Br J Haematol; 1989 Nov; 73(3):403-9. PubMed ID: 2605127
    [Abstract] [Full Text] [Related]

  • 17. Can deferoxamine be considered an ototoxic drug?
    Masala W, Meloni F, Gallisai D, Careddu M, Secchi G, Cuccuru GB, Loriga V, Salvo G.
    Scand Audiol Suppl; 1988 Nov; 30():237-8. PubMed ID: 3227279
    [Abstract] [Full Text] [Related]

  • 18. Chelation therapy in beta-thalassemia: the benefits and limitations of desferrioxamine.
    Giardina PJ, Grady RW.
    Semin Hematol; 1995 Oct; 32(4):304-12. PubMed ID: 8560288
    [Abstract] [Full Text] [Related]

  • 19. Combined chelation therapy with deferoxamine and deferiprone in β-thalassemia major: compliance and opinions of young thalassemic patients.
    Hatzipantelis ES, Karasmanis K, Perifanis V, Vlachaki E, Tziomalos K, Economou M.
    Hemoglobin; 2014 Oct; 38(2):111-4. PubMed ID: 24351163
    [Abstract] [Full Text] [Related]

  • 20. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
    Daar S, Pathare AV.
    Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.